HLA-A2限制性CTL表位HPV18E7_(7-15)分子修饰肽的免疫原性鉴定  

Identification on Immunogenicity of Molecular Modification of the Cytotoxic T Lymphocyte Epitope HPV18E7_(7-15) Restricted by HLA-A2

作　　者：邵笑红[1] 欧荣英[1] 徐云升[1] 张学奇[1] 蔡剑峰[1] 李秉煦[1] 

机构地区：[1]温州医学院附属第一医院皮肤性病科,温州325000

出　　处：《浙江中西医结合杂志》2010年第12期739-741,共3页Zhejiang Journal of Integrated Traditional Chinese and Western Medicine

基　　金：温州市科技计划项目(No.Y20080171;Y20080146)

摘　　要：目的:对HLA-A2限制性细胞毒性T淋巴细胞(cytotoxic T lymphocyte,CTL)表位HPV18E77-15进行氨基酸置换修饰,探讨修饰肽的免疫原性。方法:采用细胞毒实验(51Cr释放法),以包被了九肽的T2细胞作为靶细胞,以九肽诱导的HLA-A2阳性人外周血单个核细胞为效应细胞,观察目标肽是否具有诱导特异性CTL杀伤效应。结果:修饰肽符合HLA-A2分子限制性细胞毒性T细胞的表位要求,具有特异性细胞毒性T细胞诱导活性。结论:修饰肽具有较强的抗原性,可以作为高危型HPV感染治疗性肽疫苗分子设计的候选表位。Objective：To investigate the immunogenicity of peptide modified by amino acid substitution for the cytotoxic T lymphocytes（CTLs） epitope HPV18E77-15 restricted by HLA-A2. Methods：51Cr release assay was used to determine their abilities of inducing the generation of specific CTLs. Results：The modified peptide TLQDIVLHV met the requirements of HLA-A2-restricted CTL epitopes and had the abilitiy of inducing the generation of specific CTLs. Conclusion：The modified peptide TLQDIVLHV may have better antigenicity and affinity to HLA-A2,and can be used as one of the HLA-A2 restricted candidate epitopes for therapeutic peptide vaccine against HPV infection.

关 键 词：人乳头状瘤病毒 E7抗原 表位 HLA-A2 CTL 免疫原性 分子修饰 

分 类 号：R392[医药卫生—免疫学]